ClinicalTrials.gg
RecruitingNCT07013435Updated Oct 26, 2026

A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship

An interventional study of Health Education Program and SMART3RP-Lymphoma in Lymphoma, sponsored by Massachusetts General Hospital. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 26, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Lymphoma by Massachusetts General Hospital — 4 open to participants now, 5 under way, none of them phase 3. Lymphoma · Massachusetts General Hospital.

Planned enrollment
2nd of 23
254 · median 18
Started
2026
with 2 others
No phase
9 of 24
3 open now
Registered
22nd of 24
by date

Among the 24 studies in Lymphoma by Massachusetts General Hospital, this one is the 2nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, and was the 22nd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

4 of the 24 studies in Lymphoma by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lymphoma by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The goal of this trial is to learn if a resilience intervention can lead to improvements in lymphoma survivors' quality of life.

Read the detailed description

The Stress Management and Relaxation Response Resiliency Program for lymphoma survivors (SMART3RP-Lymphoma) was adapted by researchers at the MGH. This group program seeks to buffer stress and promote psychological resiliency and physical well-being through a variety of mind-body approaches, such as imagery, relaxation, and yoga, cognitive behavioral strategies, and positive psychology tools.

The main questions it aims to answer are:

  • Will survivors randomized to SMART3RP-Lymphoma demonstrate greater improvements in quality of life when compared to survivors randomized to a Health Education Program?
  • Will improvements in resiliency lead to improvements in quality of life?

To answer these questions, researchers will compare a resilience intervention tailored to the needs of lymphoma survivors (SMART3RP-Lymphoma) to a Health Education Program to see how they affect quality of life of lymphoma survivors.

Participants will:

  • Fill out 4 surveys across 12 months
  • Participate in 8 weekly, virtual group sessions
  • Submit hair cortisol samples
03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • quality of life
  • psychosocial intervention
  • supportive care
  • cancer survivorship
  • resilience
04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English or Spanish speaking adults (18+ at time of enrollment)
  • Within 1-5 years of completing active treatment for lymphoma (includes surgery, chemotherapy, immunotherapy, radiation therapy, or other); individuals may be on maintenance treatment.

Exclusion criteria

Exclusion Criteria:

  • Active psychiatric, medical concern or cognitive comorbidity as determined by the site PI or treating clinician
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
254 participants (estimated)

Study arms

  • Active comparator
    Health Education Program

    Participants will participate in 8 weekly sessions. Components include: * education on the co-occurrence of mental and physical problems * goal setting for health behavior change * self-monitoring HEP is an active control condition for mind body programs and is structurally equivalent to SMART3RP

    Other: Health Education Program

  • Experimental
    SMART3RP-Lymphoma

    Participants will participate in 8 weekly sessions. The intervention components include: * Eliciting the relaxation response (RR), * CBT strategies to improve stress management * Positive psychology strategies to achieve growth enhancement

    Other: SMART3RP-Lymphoma

Interventions

  • OtherHealth Education Program

    8 weekly sessions that include education on the co-occurrence of mental and physical problems, goal setting for health behavior change, and self-monitoring. Each session includes basic didactic information, interactive application of the information, and open discussion of didactic material.

  • OtherSMART3RP-Lymphoma

    The SMART3RP-lymphoma is a group program that, through a variety of mind-body approaches, such as imagery, relaxation, and yoga, seeks to buffer stress and promote psychological resiliency and physical well-being.

06

What researchers measure

Primary outcomes

  1. Quality of Life (QoL): Change in PROMIS-29

    To examine the effects of the SMART3RP-Lymphoma vs. a Health Education Program (HEP) in improving quality of life in early posttreatment lymphoma survivors. Quality of life will be measured using the PROMIS-29 which assesses physical, functional, emotional, and social quality of life. Each survey item is measured on a 1-5 scale. The unit of measurement is a score on a scale.

    Time frame: From enrollment to 6 month follow up

Secondary outcomes

  1. Resilience: Change in Scores on the Current Experiences Scale (CES)

    To compare the effects of the SMART3RP-Lymphoma vs. a Health Education Program (HEP) on resilience in posttreatment lymphoma survivors. Resilience will be measured by the Current Experiences Scale (CES). The CES is a 23-item measure that assesses the following domains of resilience on 0-5 scale: appreciation for life, adaptive perspectives, personal strength, spiritual connectedness, relating to others, and health behaviors. The unit of measurement is a score on a scale.

    Time frame: Enrollment to 3 month follow up

Other outcomes

  1. Correlation between scores on measures of Resilience (CES) and Quality of Life (PROMIS-29)

    The investigators will determine how resilience at 3 months correlates to quality-of-life improvements at 6 and 12 months. Resilience will be measured by the Current Experiences Scale (CES), which is a 23-item measure. The CES assesses 6 domains of resilience including appreciation for life, adaptive perspectives, personal strength, spiritual connectedness, relating to others, and health behaviors). Quality of life will be measured by the PROMIS-29 which is a 29-item measure. It assesses physical, functional, emotional, and social quality of life domains. The unit of measurement for both assessments are scores on a scale.

    Time frame: 3, 6 and 12 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — de-identified information as required by the NIH

Supporting information: Study protocol, Statistical analysis plan

Time frame: Information will be made available as required by the NIH in public repository and via clinicaltrials.gov

Access criteria: Researchers submitting formal requests as required and allowable by the NIH will be able to access supporting information.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2029, 35 months after the start.

Of 161 non-industry interventional studies with no phase under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 87. This study's planned 35 months is below that.

Counting every sponsor, half of 170 studies reached it within 43 months; a quarter within 23 and three quarters within 87.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2025
First posted
Jun 10, 2025
StartActual
Oct 6, 2026was Aug 2026
Primary completionEst.
Sep 2029
CompletionEst.
Aug 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
2 sites added. Mass General Hospital is now Recruiting
Show 2 added (2 United States)
  • Huntsman Cancer Institute · Salt Lake City, United States
  • Sylvester Comprehensive Cancer Center · Miami, United States
across 2 updates, Sep 28, 2026 – Oct 26, 2026
Start date
Aug 31, 2026→Oct 6, 2026 (actual)
moved 2 times, Sep 28, 2026 – Oct 8, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedWithin 21-5 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy, immunotherapy, radiation therapy, or other); individuals may be on maintenance treatment.
Exclusion criteria
  • EditedActive psychiatric, medical concern or cognitive comorbidity as determined by the site PI or treating clinician
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Mass General Hospital · Boston, United StatesContact none listed→•••0765
Sep 28, 2026
Show all 3 updates
  1. Oct 26, 2026
    1 site added
    Show site
    • Sylvester Comprehensive Cancer Center · Miami, United States
  2. Oct 8, 2026
    Start date Oct 1, 2026→Oct 6, 2026 (now actual)
    + 1 other change: verification date
  3. Sep 28, 2026
    Not yet recruiting→Recruiting
    1 site added. Mass General Hospital is now Recruiting
    Show site
    • Huntsman Cancer Institute · Salt Lake City, United States
    Start date Aug 31, 2026→Oct 1, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedWithin 21-5 years of completing active, curative treatment for lymphoma (includes surgery, chemotherapy, immunotherapy, radiation therapy, or other); individuals may be on maintenance treatment.
    Exclusion criteria
    • EditedActive psychiatric, medical concern or cognitive comorbidity as determined by the site PI or treating clinician
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mass General Hospital · Boston, United StatesContact none listed→•••0765
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07013435
Responsible party
Giselle K. Perez Lougee (Clinical Psychologist, Massachusetts General Hospital) — Principal investigator
First posted
Jun 10, 2025
Start date
Oct 6, 2026
Primary completion
Sep 2029 (estimated)
Completion
Aug 2030 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion